Last reviewed · How we verify
Nicotinamide treatment — Competitive Intelligence Brief
phase 3
Vitamin B3 / NAD+ precursor
NAD+ biosynthesis pathway
Small molecule
Live · refreshed every 30 min
Target snapshot
Nicotinamide treatment (Nicotinamide treatment) — Assistance Publique - Hôpitaux de Paris. Nicotinamide replenishes NAD+ cofactor pools to support cellular energy metabolism and DNA repair pathways.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nicotinamide treatment TARGET | Nicotinamide treatment | Assistance Publique - Hôpitaux de Paris | phase 3 | Vitamin B3 / NAD+ precursor | NAD+ biosynthesis pathway |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Vitamin B3 / NAD+ precursor class)
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nicotinamide treatment CI watch — RSS
- Nicotinamide treatment CI watch — Atom
- Nicotinamide treatment CI watch — JSON
- Nicotinamide treatment alone — RSS
- Whole Vitamin B3 / NAD+ precursor class — RSS
Cite this brief
Drug Landscape (2026). Nicotinamide treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotinamide-treatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab